spacer
home > ebr > autumn 2009 > investigating interactions
PUBLICATIONS
European Biopharmaceutical Review

Investigating Interactions

 

As a result of scientific efforts over the last few decades, the Protein Data Bank (PDB) library now contains descriptions of more than 48,000 high-resolution biomolecular structures (1). In addition, characterisation data for more than 38,000 of the estimated 300,000 protein-protein interactions in humans has been collected (2). This information is critical to our understanding of interactions between proteins and in the investigation of the effects of these interactions, from academic research to drug discovery and development. Based on the report by Prasad et al, it can be calculated that only around six per cent of the identified interactions have been confirmed in vivo and with the use of several in vitro techniques (2). Thus, although a significant number of interactions are already well-characterised, there is still a need for additional experimental verification.

As well as the need for investigation of protein structure-function relationships and the mapping of the interactome to increase our biological understanding, there is also a growing demand from regulatory authorities to employ orthogonal approaches to biotherapeutic discovery and development. Complementary methods are needed to enable researchers to validate and verify interaction data, and to make confident conclusions and decisions in the drug development process.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Thomas Lundbäck is a Senior Project Manager at GE Healthcare, Life Sciences. He recently joined GE Healthcare from Biovitrum, where he held the positions of project leader and principal scientist, implementing different biophysical techniques. Thomas has a PhD in biophysical chemistry from the Karolinska Institute in Stockholm, Sweden. He is also a member of the Industrial Research Committee at the Royal Swedish Academy of Engineering Sciences (IVA), which represents research areas of future strategic interest for Swedish industry.
spacer
Thomas Lundbäck
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

PCI Pharma Services Announces Organization Updates

Philadelphia, PA – May 20, 2019 – PCI Pharma Services, a leading biopharmaceutical outsourcing services provider, is pleased to announce the following management updates to help drive the company’s future vision, strategy and growth.
More info >>

White Papers

Clinical Trials in Russia Orange Paper: 1st Quarter 2014

Synergy Research Group

In summary, Russia remains a very popular geography for local, regional, and global pharmaceutical companies to conduct clinical trials. Sponsors mention the following reasons for conducting studies in Russia: 1. Fast patient enrollment due to the centralized medical infrastructure. 2. Nearly 100% patient retention 3. GCP trained and certified Investigative Sites generating high quality data 4. Low cost: Average per patient cost is 60% to 70% below US and European prices due to the low cost of Investigators and the high concentration of patients in therapeutically aligned medical centers
More info >>

 
Industry Events

2020 Avoca Quality and Innovation Summit

3-4 June 2020, Amsterdam, The Netherlands

The 2020 Avoca Quality and Innovation Summit will take place 3-4 June 2020, in Amsterdam, The Netherlands.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement